



Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel's Third Annual CNS Day on March 31st

March 18, 2021

DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at Stifel's Third Annual CNS Day, which is being held on March 31st.

Avadel's fireside chat is scheduled for 3 p.m. ET on Wednesday, March 31st. A live webcast of this event, as well as an archived recording, will be available at ([click here](#)), as well as on Avadel's website, www.avadel.com, for 90 days from being made available.

Contacts:

Tom McHugh

Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com

Tim McCarthy

LifeSci Advisors, LLC
Phone: (212) 915-2564
Email: tim@lifesciadvisors.com



Source: Avadel Pharmaceuticals plc